Literature DB >> 19822232

Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332.

H A Balogun1, N-M Vasconcelos, R Lindberg, M Haeggström, K Moll, Q Chen, M Wahlgren, K Berzins.   

Abstract

Antigen Pf332, a megadalton protein has been shown to be associated with the membrane of infected erythrocytes. Detailed functional studies on the antigen have remained hampered by the cross-reactive nature of antibodies generated to Pf332. Pf332-C231, identified in the C-terminal region of Pf332 was cloned and antibodies against the C231 fragment were shown to react with intact Pf332 antigen by both immunofluorescence and immunoblotting analyses. Antibodies to C231 inhibited in vitro Plasmodium falciparum growth efficiently. In addition, human sera from malaria-exposed individuals reacted with recombinant C231. We show that Pf332-C231 represents a functional domain and is expected to facilitate further studies on Pf332 as a potential target for protective immune responses and the function of the antigen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822232     DOI: 10.1016/j.vaccine.2009.09.110

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Characterization of the Duffy-Binding-Like Domain of Plasmodium falciparum Blood-Stage Antigen 332.

Authors:  Sandra Nilsson; Kirsten Moll; Davide Angeletti; Letusa Albrecht; Inari Kursula; Ning Jiang; Xiaodong Sun; Klavs Berzins; Mats Wahlgren; Qijun Chen
Journal:  Malar Res Treat       Date:  2011-09-19

2.  PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen.

Authors:  Xin Zhao; Zhiguang Chang; Zhiwei Tu; Shengchao Yu; Xiaoyan Wei; Jianhua Zhou; Huijun Lu; Ning Jiang; Qijun Chen
Journal:  Malar J       Date:  2014-12-12       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.